The Food and Drug Administration (FDA) has announced a significant change in how it conducts drug testing. Starting Thursday, the agency will phase out animal testing for certain antibody therapies. Instead, it will use lab-grown human organoids, which are clusters of human cells that mimic actual organs.
This decision comes as part of a broader effort to modernize drug evaluation processes. FDA Commissioner Dr. Martin Makary emphasized that this shift aims to accelerate the development of treatments while also reducing the reliance on animal testing. He stated that many drugs already have extensive data from international human use, making additional animal testing unnecessary.
Dr. Makary explained that the new approach will utilize advanced technology, including artificial intelligence and human organ models, to better understand how drugs work in the human body. This method is expected to speed up the process of getting safer treatments to patients, potentially lowering research and development costs and drug prices.
The FDA’s focus will primarily be on monoclonal antibody therapies, which are designed to help the immune system fight diseases like cancer. By using organoids, the FDA hopes to reveal toxic effects that might not be detected in animal testing, providing clearer insights into human responses.
This change reflects a growing trend in the medical field to prioritize ethical practices and improve the reliability of drug testing. As the FDA moves forward with this initiative, it signals a commitment to advancing public health while also addressing ethical concerns related to animal testing.